Folic Acid and Vitamin B12 Supplementation on Male Patients with Schizophrenia Predominant Negative Symptoms

Author(s): Rona Hanani Simamora*, Bahagia Loebis, Muhammad Surya Husada, Elmeida Effendy.

Journal Name: Current Nutrition & Food Science

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Schizophrenia is a chronic mental disorder that affects approximately 1% of the world’s population. Particularly, negative symptoms are frequently resistant and are the main contributors to the disability on schizophrenia patients. Folic acid and vitamin B12 supplementation is the safe and affordable approach, which can significantly improve the outcome on the patients with residual symptoms.

Objectives: We aimed to understand the difference of negative subscale of Positive and Negative Syndrome Scale (PANSS) Score on patients with schizophrenia who receive risperidone with the addition folic acid and Vitamin B12 and patients who receive only risperidone after 6 weeks.

Methods: This study is a quasi experimental pre-test and post-test designs that are divided into two groups, they are group receiving risperidone with the addition of folic acid and vitamin B12 and the group receiving only risperidone. Diagnosis of schizophrenia according to the International Classification of Diseases (ICD-10) criteria and negative symptoms assessed by using negative subscale of PANSS Scores are observed. Statistical analysis is conducted using Statistical Package for the Social Sciences (SPSS) software.

Results: There was a significant difference in the mean score of negative-scale PANSS scores at the end of week 6 between the group receiving folic acid and vitamin B12 supplementation and the group receiving only risperidone with p = 0.002; p <0.05.

Conclusion: Folic acid and vitamin B12 Supplementation provide benefits to patients schizophrenia.

Keywords: Folic acid, homocysteine, negative symptom, risperidone, schizophrenia, vitamin B12.

[1]
Brown HE, Roffman JL. Vitamin supplementation in the treatment of schizophrenia. CNS Drugs 2014; 28(7): 611-22.
[http://dx.doi.org/10.1007/s40263-014-0172-4] [PMID: 24846474]
[2]
Sadock BJ, Sadock VA, Ruiz P. Schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P, Eds Kaplan & Sadock’s synopsis of psychiatry behavioral sciences/clinical psychiatry. 11th ed. Lippincott Williams & Wilkins Philadelphia. 2015; pp. 649-701.
[3]
Wechter A, Gardner KN, Grove TB, et al. Schizophrenia and folate pharmacogenetics: review of the literature regarding folic acid and its pharmacogenetically regulated metabolism in relation to schizophrenia treatments. Mental Health Clinician 2012; 1(9): 225-9.
[http://dx.doi.org/10.9740/mhc.n99731]
[4]
Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull 2011; 37(2): 291-9.
[http://dx.doi.org/10.1093/schbul/sbq104] [PMID: 20861151]
[5]
Fusar-Poli P, Papanastasiou E, Stahl D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015; 41(4): 892-9.
[http://dx.doi.org/10.1093/schbul/sbu170] [PMID: 25528757]
[6]
Velligan DI, Alphs LD. Negative symptoms in schizophrenia: an update on identification treatment. Schizophrenia Psychopharmacol 2014; 31(11): 1-7.
[7]
Kaiser S, Heekeren K, Simon JJ. The negative symptoms of schizophrenia: category or continuum? Psychopathology 2011; 44(6): 345-53.
[http://dx.doi.org/10.1159/000325912] [PMID: 21847001]
[8]
World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)- WHO Version for 2016 [Internet] 2016.Available from:. http://apps.who.int/classifications/icd10/browse/2016/en#F20
[9]
Torrey EF, Davis JM. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses 2012; 5(4): 208-16.
[http://dx.doi.org/10.3371/CSRP.5.4.5] [PMID: 22182458]
[10]
[No authors listed]. Folic acid. Monograph. Altern Med Rev 2005; 10(3): 222-9.
[PMID: 16164377]
[11]
Masters SB. Agents used in anemias; hematopoietic growth factors Basic and Clinical Pharmacology. 12th ed. Mc Graw Hill Lange New York. 2010; pp. 581-99.
[12]
Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misiak B. Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Front Behav Neurosci 2014; 8: 343.
[http://dx.doi.org/10.3389/fnbeh.2014.00343] [PMID: 25339876]
[13]
Borba CP, Fekadu A, Teferra S, et al. A placebo-controlled trial of folate with B12 in patients with schizophrenia with residual symptoms in Ethiopia using a sequential parallel comparison design. Br J Med Med Res 2014; 4(23): 4090-104.
[http://dx.doi.org/10.9734/BJMMR/2014/10473]
[14]
Ramachandran P, Thirunavakarasu P. Vitamins in schizophrenia: a literature review. AP J Psychological Medicine 2012; 13(2): 74-9.
[15]
Wang D, Zhai JX, Liu DW. Serum folate levels in schizophrenia: a meta-analysis. Psychiatry Res 2016; 235(235): 83-9.
[http://dx.doi.org/10.1016/j.psychres.2015.11.045] [PMID: 26652840]
[16]
Dietrich-Muszalska A, Malinowska J, Olas B, et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res 2012; 37(5): 1057-62.
[http://dx.doi.org/10.1007/s11064-012-0707-3] [PMID: 2270909]
[17]
Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(6): 1289-96.
[http://dx.doi.org/10.1016/j.pnpbp.2007.05.011] [PMID: 17597277]
[18]
Hill M, Shannahan K, Jasinski S, et al. Folate supplementation in schizophrenia: a possible role for MTHFR genotype Schizophr Res. 2011; 127(1-30): 41-5.
[http://dx.doi.org/10.1016/j.schres.2010.12.006]
[19]
Saedisomeolia A, Djalali M, Moghadam AM, Ramezankhani O, Najmi L. Folate and vitamin B12 status in schizophrenic patients. J Res Med Sci 2011; 16(Suppl. 1): S437-41.
[PMID: 22247731]
[20]
Roffman JL, Lamberti JS, Achtyes E, et al. Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 2013; 70(5): 481-9.
[http://dx.doi.org/10.1001/jamapsychiatry.2013.900] [PMID: 23467813]
[21]
Pai NB, Vella SLC. Negative symptoms in schizophrenia: the prevailing challenge. Nitte Univ J Health Sci 2015; 5(2): 104-15.
[22]
Sarkar S, Hillner K, Velligan DI. Conceptualization and treatment of negative symptoms in schizophrenia. World J Psychiatry 2015; 5(4): 352-61.
[http://dx.doi.org/10.5498/wjp.v5.i4.352] [PMID: 26740926]
[23]
Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 2014; 5(47): 47.
[http://dx.doi.org/10.3389/fpsyt.2014.00047] [PMID: 24904434]
[24]
Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: an update. Pharmacol Ther 2015; 153: 135-47.
[http://dx.doi.org/10.1016/j.pharmthera.2015.06.008] [PMID: 26116809]
[25]
Mucci A, Merlotti E, Üçok A, Aleman A, Galderisi S. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res 2017; 186(186): 19-28.
[http://dx.doi.org/10.1016/j.schres.2016.05.014] [PMID: 27242069]
[26]
Remington G, Foussias G, Fervaha G, et al. Treating negative symptoms in schizophrenia: an update. Curr Treat Options Psychiatry 2016; 3: 133-50.
[http://dx.doi.org/10.1007/s40501-016-0075-8] [PMID: 27376016]
[27]
Fisekovic S, Serdarevic N, Memic A, et al. Correlation between serum concentrations of homocysteine, folate and vitamin B12 in patients with schizophrenia. J Health Sci 2013; 3(2): 139-44.
[http://dx.doi.org/10.17532/jhsci.2013.78]
[28]
Kim TH, Moon SW. Serum homocysteine and folate levels in Korean schizophrenic patients. Psychiatry Investig 2011; 8(2): 134-40.
[http://dx.doi.org/10.4306/pi.2011.8.2.134] [PMID: 21852990]
[29]
Misiak B, Frydecka D, Łaczmański Ł, Ślęzak R, Kiejna A. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol 2014; 70(12): 1433-41.
[http://dx.doi.org/10.1007/s00228-014-1762-2] [PMID: 25291992]
[30]
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48(3): 143-57.
[http://dx.doi.org/10.2165/00003088-200948030-00001] [PMID: 19385708]
[31]
Ruiz-Iriondo M, Salaberria K, Echeburúa E. Schizophrenia: analysis and psychological treatment according to the clinical staging. Actas Esp Psiquiatr 2013; 41(1): 52-9.
[PMID: 23440536]
[32]
Belcastro V, Striano P. Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy. Epilepsy Res 2012; 102(1-2): 1-7.
[http://dx.doi.org/10.1016/j.eplepsyres.2012.07.003] [PMID: 22824326]
[33]
Departement of health and human services centers for disease control and prevention. Body Mass Index: considerations for practitioners. Available from https://www.cdc.gov/obesity/ downloads/bmiforpactitioners.pdf
[34]
Naja WJ, Halaby A. Anticholinergic use and misuse in psychiatry: a comprehensive and critical review. J Alcohol Drug Depend 2017; 5(2): 1-4.
[http://dx.doi.org/10.4172/2329-6488.1000263]
[35]
Winkels RM, Brouwer IA, Verhoef P, van Oort FV, Durga J, Katan MB. Gender and body size affect the response of erythrocyte folate to folic acid treatment. J Nutr 2008; 138(8): 1456-61.
[http://dx.doi.org/10.1093/jn/138.8.1456] [PMID: 18641191]
[36]
Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161(9): 1705-8.
[http://dx.doi.org/10.1176/appi.ajp.161.9.1705] [PMID: 15337665]
[37]
Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry 2006; 60(3): 265-9.
[http://dx.doi.org/10.1016/j.biopsych.2005.10.009] [PMID: 16412989]
[38]
Fenech M. Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity. Mutat Res 2012; 733(1-2): 21-33.
[http://dx.doi.org/10.1016/j.mrfmmm.2011.11.003] [PMID: 22093367]
[39]
Cao B, Wang DF, Xu MY, et al. Lower folate levels in schizophrenia: A meta-analysis. Psychiatry Res 2016; 245: 1-7.
[http://dx.doi.org/10.1016/j.psychres.2016.03.003] [PMID: 27521746]
[40]
Nishi A, Numata S, Tajima A, et al. Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull 2014; 40(5): 1154-63.
[http://dx.doi.org/10.1093/schbul/sbt154] [PMID: 24535549]
[41]
Kinoshita M, Numata S, Tajima A, Shimodera S, Imoto I, Ohmori T. Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. Epigenetics 2013; 8(6): 584-90.
[http://dx.doi.org/10.4161/epi.24621] [PMID: 23774737]
[42]
Ramaekers VT, Thöny B, Sequeira JM, et al. Folinic acid treatment for schizophrenia associated with folate receptor autoantibodies. Mol Genet Metab 2014; 113(4): 307-14.
[http://dx.doi.org/10.1016/j.ymgme.2014.10.002] [PMID: 25456743]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [98 - 104]
Pages: 7
DOI: 10.2174/1573401314666180620142607
Price: $65

Article Metrics

PDF: 19
HTML: 3
EPUB: 1
PRC: 1